About me
Arvin Gouw is the founding CEO of Bacchus Therapeutics, which develops small-molecule inhibitors of cancer metabolic pathways based on his findings at Stanford when he was an instructor in the oncology department. His work has been supported by the entrepreneurship program of SPARK at Stanford, MBC BioLabs, AbbVie, RAMP, and Johnson & Johnson.
Prior to Stanford and Harvard, Arvin did his fellowship on science and religion at Princeton. Arvin received his doctorate from Johns Hopkins University School of Medicine, master's degrees in philosophy from the University of Pennsylvania, theology from SMSU Ecumenical Institute of Theology, and neuroscience from UC Berkeley.